Vascular Dementias – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Vascular Dementias – Drugs In Development, 2024 report and make more profitable business decisions.
Vascular dementia (VaD) is dementia caused by problems in the blood supply to the brain, resulting from a cerebrovascular disease. Restricted blood supply (ischemia) leads to cell and tissue death in the affected region, known as an infarct. Vascular dementia can be caused by ischemic or hemorrhagic infarcts affecting multiple brain areas, including the anterior cerebral artery territory, the parietal lobes, or the cingulate gyrus.
The Vascular Dementias drugs in development market research report provide comprehensive information on the therapeutics under development for Vascular Dementias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vascular Dementias and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Vascular Dementias | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 18 molecules, with 14 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Vascular Dementias therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Vascular Dementias pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Vascular Dementias treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alector IncAriBio Co Ltd
Autifony Therapeutics Ltd
Beijing Joekai Biotechnology Co Ltd
BIOPHARMA Corp
Center for Drug Research and Development
CSPC Pharmaceutical Group Ltd
DiaMedica Therapeutics Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Guangzhou Magpie Pharmaceutical Co Ltd
Guangzhou University of Chinese Medicine
Hemostemix Inc
Max Delbruck Center for Molecular Medicine
Merz Pharma GmbH & Co KgaA
Parkure Ltd
Seoul National University
T3D Therapeutics Inc
Tisento Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Vascular Dementias reports